Drug screening model meets cancer organoid technology
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...
Main Authors: | Chen Liu, Tianyu Qin, Yuhan Huang, Yuan Li, Gang Chen, Chaoyang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-11-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303326 |
Similar Items
-
Research progress of brain organoids in drug development
by: WANG Liang, XIA Longkuo, ZHANG Jianmin
Published: (2024-09-01) -
The role of organoids in cancer research
by: Zhen Fang, et al.
Published: (2023-08-01) -
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
by: Jumpei Kondo, et al.
Published: (2019-05-01) -
Biomaterial-assisted organoid technology for disease modeling and drug screening
by: Yunyuan Shao, et al.
Published: (2025-02-01) -
Patient‐derived organoids for personalized gallbladder cancer modelling and drug screening
by: Bo Yuan, et al.
Published: (2022-01-01)